SCHEMBL25922452

SCHEMBL25922452

NC1CC(c2nc3cc(Br)ccc3s2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
DYRK1A Q13627 1/20 0.40
PPARA Q07869 2/20 0.40
LMNA P02545 2/20 0.38
UBE2M P61081 2/20 0.38
DCUN1D1 Q96GG9 2/20 0.38
TP53 P04637 1/20 0.38
ADORA1 P30542 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
MAPT P10636 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30470911 1.00 NPC1 (0.42) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL16132861 0.84 NPC1 (0.52) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL25922454 0.81 DYRK1A (0.41) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL25955539 0.81 NPC1 (0.45) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL30470444 0.81 DYRK1A (0.41) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL29081459 0.81 NPC1 (0.45) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL25324344 0.80 PPARA (0.42) RAB9ADYRK1APPARALMNAUBE2M
SCHEMBL25335753 0.80 NPC1 (0.44) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL29081669 0.80 NPC1 (0.43) NPC1RAB9ADYRK1APPARALMNA
SCHEMBL30470420 0.79 DYRK1A (0.39) NPC1RAB9ADYRK1APPARALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146989-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 NPC1 39/4885RAB9A 320/4885DYRK1A 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.